# Expert recommendations for setting and adjusting airway pressure release ventilation based on clinical experience and basic science evidence

**Authors:** Gary F. Nieman, Jason H. T. Bates, Penny L. Andrews, Louise Rose, Joseph Shiber, Joaquin Araos, Ledoux Aurelien, Maria Madden, Toni Manougian, Josh Satalin, Tero Varpula, Hassan Al-khalisy, Manjunath Markandaya, Pedro Leme Silva, Luis Felipe da Fonseca Reis, John Downs, Luigi Camporota, Nader M. Habashi

PMC · DOI: 10.3389/fmed.2026.1741129 · 2026-02-03

## TL;DR

Experts provided evidence-based recommendations for setting and adjusting APRV ventilation in patients with ARDS, integrating clinical experience and scientific evidence.

## Contribution

A novel expert consensus protocol for optimizing APRV settings in acute lung injury based on clinical and scientific evidence.

## Key findings

- Initial APRV settings include PHigh based on plateau or peak pressure, THigh matching conventional respiratory rate, PLow at 0 cmH2O, and TLow calculated from expiratory flow.
- Recommendations emphasize titration of APRV settings in response to lung physiology changes to prevent gas exchange impairment and lung instability.
- The protocol integrates clinical experience and scientific evidence to improve outcomes in patients with ARDS or increased lung elastance.

## Abstract

We conducted a roundtable discussion and provided evidence-based guidance on the setting and adjustment of Airway Pressure Release Ventilation (APRV) in adult patients with acute respiratory distress syndrome (ARDS).

A panel of clinicians and basic scientists with extensive experience in lung physiology and using APRV was assembled to provide expert consensus guidance. The panel first established and agreed upon guiding principles for optimal APRV settings. To support consensus discussions, we then reviewed the literature on the physiological basis of APRV as a lung-protective ventilation strategy, as well as published APRV research. Finally, we held a one-day meeting and conducted robust, iterative consensus discussions using the Nominal Group Technique to reach agreement on the optimal APRV settings. This work represents an Expert Recommendation and Position Statement rather than a formal consensus guideline. The recommendations were developed through iterative expert discussions that integrated extensive clinical experience with supporting basic science evidence on time-controlled ventilation and alveolar mechanics. Recommendations were based on expert experience with APRV in the intensive care unit and supported by published animal and clinical studies.

Consensus on initial APRV settings for acute lung injury (ALI) such as ARDS or disorders of normal or increased elstance was as follows: set the upper airway pressure (PHigh) to either plateau or peak inspiratory pressure when transitioning from volume control or pressure control/dual control, respectively; set the duration of PHigh (THigh) to match the current respiratory rate on conventional ventilation; set lower airway pressure (PLow) to 0 cmH2O; and calculate duration of PLow (TLow) using the equation Peak Expiratory Flow x 75% = Termination of Expiratory Flow. Other recommendations included titrating these settings in response to changes in lung physiology and reaching consensus on injurious APRV settings that could impair gas exchange or cause lung instability.

The panel developed a protocol for adjusting the four APRV settings based on expert experience and solid clinical and scientific evidence for patients with ALI and ARDS, or disorders of normal or increased elastance. Optimizing the lung-protective settings in APRV mode can improve patient outcomes.

## Linked entities

- **Diseases:** acute respiratory distress syndrome (MONDO:0006502), acute lung injury (MONDO:0006502)

## Full-text entities

- **Diseases:** alveolar collapse (MESH:D001261), ascites (MESH:D001201), gut (MESH:C536735), barotrauma (MESH:D001469), P (MESH:D002972), antiphospholipid syndrome (MESH:D016736), abdominal distension (MESH:D000007), RD (MESH:D012001), right heart dysfunction (MESH:D006331), CRS (MESH:D015619), alveolar instability (MESH:D043171), sepsis (MESH:D018805), tissue damage (MESH:D017695), inflammation (MESH:D007249), Shock Trauma (MESH:D012769), Injury (MESH:D014947), lung disease (MESH:D008171), VILI (MESH:D055397), Lung Injury (MESH:D055370), edema (MESH:D004487), pulmonary edema (MESH:D011654), ALI (MESH:D055371), obesity (MESH:D009765), respiratory failure (MESH:D012131), hypercapnia (MESH:D006935), pneumonia (MESH:D011014), ARDS (MESH:D012128), gut ischemia (MESH:D007511), hypoxemia (MESH:D000860), respiratory acidosis (MESH:D000142)
- **Chemicals:** ARPV (-), CO2 (MESH:D002245), Tween (MESH:D011136), TC (MESH:D013667), PS (MESH:D010758), H2O (MESH:D014867)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Sus scrofa (pig, species) [taxon 9823]

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12909506/full.md

---
Source: https://tomesphere.com/paper/PMC12909506